CALCIMEDICA, INC. (CALC) Reports the reporting period Financial Results
CALCIMEDICA, INC. (CALC) announced its financial results for the period ending the reporting period.
Key Financial Highlights:
Revenue: Not disclosed
Net Income: $7
EPS: Not disclosed
Cash and equivalents: 18617
targeting multiple disease drivers, including right ventricular dysfunction, which is the principal driver of mortality and not directly targeted by existing therapies. In acute pancreatitis, FDA alignment on the Phase 2b trial endpoints and patient enrichment strategy provides a clear framework for the next stage of development in a disease with no approved therapies. With Auxora PAH data and the CM5480
anticipated in mid-2027
targeting key drivers of disease progression. CalciMedica is advancing CM5480
📋 CALCIMEDICA, INC. (CALC) - Financial Results
Filing Date: 2026-08-11
Accepted: 2026-08-11 07:15:17
Event Type: Financial Results
Event Details:
📊 Key Financial Metrics (Year-over-Year Comparison):
💼 Business Developments:
Structured Data: